ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-OR22

University of California Health Systems Kidney COVID Study Inpatient Cohort

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Hamdan, Hiba, UC Davis Health, Sacramento, California, United States
  • Paciotti, Brian Michael, UC Davis Health, Sacramento, California, United States
  • Durbin-Johnson, Blythe, UC Davis Health, Sacramento, California, United States
  • Young, Brian Y., UC Davis Health, Sacramento, California, United States
  • Moreno-Ortiz, Juan Pablo, UC Davis Health, Sacramento, California, United States
  • Roshanravan, Baback, UC Davis Health, Sacramento, California, United States

Understanding long term changes in kidney function following moderate to severe COVID-19 is important. The aim of our study was to compare changes in eGFR between people hospitalized with and without COVID-19 to better understand its longer-term kidney sequelae.


We conducted a retrospective cohort study of adults receiving care within the five major University of California (UC) Health Systems, who underwent PCR testing for SARS-CoV-2 between March 1, 2020, and December 31, 2021, and were hospitalized within 10 days of testing. The cohort was restricted to those without ESKD, with a serum creatinine (sCr) within 12 months prior to SARS-CoV-2 testing or normal kidney function on admission, length of stay ≥1 day, no pregnancy throughout the study period, and at least one outpatient sCr 30 days after initial PCR test. Individuals were classified as COVID/non-COVID based on the index SARS-CoV-2 PCR result and those classified as non- COVID were required to remain negative. The outcome was the difference in the rate of eGFR change among those who survived hospitalization. The cohort was followed until December 31, 2022. Descriptive statistics were used to compare patient characteristics. Trajectories of eGFR were compared between those with and without COVID using linear mixed models with inverse probability weighting to account for missingness of baseline and follow-up eGFR measurements. Three linear mixed models were fitted as detailed in attached figure.


The cohort included 2,356 and 26894 patients hospitalized with and without COVID, respectively. Patients hospitalized with COVID-19 were more likely to be male, Hispanic, reside in areas with higher Area deprivation index (ADI), and have pre-existing chronic diseases, including DM, HTN and CKD. The results of the three fitted models are shown in attached figure.


In a large cohort from one of the largest health care systems in California, we did not observe a significant difference in eGFR decline over almost 2 years of follow up. This study has the longest reported follow up of kidney function post SARS COV 2 infection.

LME Models


  • Other NIH Support